Korean J Physiol Pharmacol 2022; 26(5): 347-355
Published online September 1, 2022 https://doi.org/10.4196/kjpp.2022.26.5.347
Copyright © Korean J Physiol Pharmacol.
Ke Tao1,#, Ming Li1,#, Xuefeng Gu1, Ming Wang1, Tianwei Qian1, Lijun Hu1, and Jiang Li2,*
1Department of General Surgery, Changshu Hospital Affiliated to Soochow University, Changshu 215500, 2Department of Vascular Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou 215008, China
Correspondence to:Jiang Li
E-mail: Maximus2018@foxmail.com
Author contributions: K.T. and M.L. conceived and designed the experiments. K.T., M.L., X.G., M.W., T.Q., L.H., and J.L. carried out the experiments. K.T., M.L., and J.L. analyzed the data. K.T., M.L., and J.L. drafted the manuscript. All authors agreed to be accountable for all aspects of the work. All authors have read and approved the final manuscript.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abdominal aortic aneurysm (AAA) is a life-threatening disorder worldwide. Fibroblast growth factor 21 (FGF21) was shown to display a high level in the plasma of patients with AAA; however, its detailed functions underlying AAA pathogenesis are unclear. An in vitro AAA model was established in human aortic vascular smooth muscle cells (HASMCs) by angiotensin II (Ang-II) stimulation. Cell counting kit-8, wound healing, and Transwell assays were utilized for measuring cell proliferation and migration. RT-qPCR was used for detecting mRNA expression of FGF21 and activating transcription factor 4 (ATF4). Western blotting was utilized for assessing protein levels of FGF21, ATF4, and markers for the contractile phenotype of HASMCs. ChIP and luciferase reporter assays were implemented for identifying the binding relation between AFT4 and FGF21 promoters. FGF21 and ATF4 were both upregulated in Ang-II-treated HASMCs. Knocking down FGF21 attenuated Ang-II-induced proliferation, migration, and phenotype switch of HASMCs. ATF4 activated FGF21 transcription by binding to its promoter. FGF21 overexpression reversed AFT4 silencing-mediated inhibition of cell proliferation, migration, and phenotype switch. ATF4 transcriptionally upregulates FGF21 to promote the proliferation, migration, and phenotype switch of Ang-II-treated HASMCs.
Keywords: Abdominal aortic aneurysm, Activating transcription factor 4, FGF21, Phenotype switch, VSMCs
Fibroblast growth factor 21 (FGF21) is a secreted endocrine factor that acts as a pivotal regulator of metabolic function [1]. FGF21 has been indicated to be implicated in a diversity of biological processes, such as autophagy and apoptosis [2,3]. FGF21 alleviates endoplasmic reticulum stress-induced apoptosis to mitigate vascular calcification in rats [4]. FGF21 attenuates high-fat diet-mediated endothelial dysfunction by upregulating antioxidant genes in apolipoprotein E-deficient mice [5]. Moreover, FGF21 ameliorates hypertension and vascular dysfunction induced by angiotensin II (Ang-II) in mice by activating angiotensin-converting enzyme 2/angiotensin-(1-7) axis [6]. The evidence indicates that FGF21 exerts a critical role in vascular diseases. Importantly, it was shown that FGF21 displayed a high level in the plasma of patients with abdominal aortic aneurysm (AAA) in comparison to that in the control groups and FGF21 high expression was closely associated with clinical characteristics of AAA [7]. Nevertheless, the detailed function of FGF21 in AAA is unclear.
Activating transcription factor 4 (ATF4) is a multifunctional transcription regulatory protein involved in diverse biological processes in response to various stimuli [8]. It has been illustrated that metformin can induce FGF21 upregulation in an ATF4-dependent manner [9]. Moreover, FGF21 promoter has three response elements for ATF4, indicating that ATF4 may be implicated in regulating FGF21 expression [10]. Additionally, ATF4 was shown to be upregulated in a mouse AAA model induced by Ang-II [11]. However, whether ATF4 can regulate FGF21 expression in AAA is unclarified.
Vascular smooth muscle cells (VSMCs) are the main inherent cells in the tunica media of abdominal wall, and it was reported that dysfunction of VSMCs contributed to the pathogenesis of AAA [12]. Ang-II, a vasoactive peptide, exerts a crucial effect on the pathophysiological development of AAA; Ang-II-induced AAA models have been used in many studies for investigating AAA [13-15].
Herein, we probed the functions of FGF21 in an Ang-II-induced
Primary HASMCs were obtained from American Type Culture Collection (PCS-100-012; ATCC, Manassas, VA, USA) and incubated in Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Hyclone, Salt Lake City, UT, USA) and 1% penicillin-streptomycin (Invitrogen) at 37°C in a humidified incubator with 5% CO2. Cells at passage 3–5 were used for subsequent experiments. Cells were treated with different concentrations of Ang-II (0–100 nM; Sigma, St. Louis, MO, USA) for 24 h. In some experiments, HASMCs were stimulated with 100 nM Ang-II for 24 h to mimic AAA
Total RNA was isolated from HASMCs using TRIzol reagent (Thermo Scientific, Waltham, MA, USA). Approximately 1 μg of total RNA was reverse transcribed with M-MLV-reverse transferase using the PrimeScript RT Reagent Kit (Takara, Dalian, China) to obtain cDNA. RT-qPCR was implemented with 2X Power SYBR-Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) on a CFX96TM Real‐Time PCR Detection System (Bio‐Rad, Hercules, CA, USA). Relative expression of FGF21 and ATF4 was computed using the 2–ΔΔCt method and normalized to GAPDH. Primer sequences are listed as follows:
FGF21
Forward: 5’-GTCAAGACATCCAGGTTCC-3’
Reverse: 5’-AGTGGAGCGATCCATACAG-3’
ATF4
Forward: 5’-CAAGGAGGATGCCTTCTCC-3’
Reverse: 5’-GTCGAACTCCTTCAAATCCA-3’
GAPDH
Forward: 5’-TCAAGATCATCAGCAATGCC-3’
Reverse: 5’-CGATACCAAAGTTGTCATGGA-3’
Proteins were extracted from HASMCs using RIPA buffer (Beyotime, Shanghai, China) and quantified with a BCA assay kit (Bio-Rad). Equal amounts of protein samples (20 μg) were resolved by 10% SDS-PAGE and transferred onto polyvinylidene difluoride membranes (Thermo Scientific). After blocked with 5% defatted milk, the membranes were incubated at 4°C overnight with primary antibodies against: FGF21 (ab171941, 1:1,000), ATF4 (ab184909, 1:1,000), α-SMA (ab124964, 1:10,000), SM22α (ab155272, 1:1,000), Tubulin (ab176560, 1:2,000) (all from Abcam, Cambridge, MA, USA), followed by incubation with the secondary antibody (ab96899; Abcam). Eventually, protein bands were visualized with an enhanced chemiluminescence kit (Fdbio Science, Hangzhou, China) and quantified with ImageJ software (GE Healthcare, Beijing, China).
To knock down FGF21 or ATF4, small interference RNA targeting FGF21 (si-FGF21) or ATF4 (si-ATF4) and corresponding negative controls (si-NC) were transfected into HASMCs. PcDNA3.1/FGF21 and empty pcDNA3.1 vector were transfected into HASMCs for overexpressing FGF21. All plasmids were obtained from GenePharma (Shanghai, China). Cell transfection was implemented using Lipofectamine 2000 (Invitrogen). After 48 h, the transfection efficiency was detected by RT-qPCR.
HASMCs with indicated treatment were inoculated in 96-well plates (2 × 105 cells/well) and incubated for 24 h. Then, CCK-8 solution (10 μl; Dojindo, Kumamoto, Japan) was added to each well and cultured for another 2 h at 37°C. The optical density was measured at 450 nm using a microplate reader (BMG Labtech, Offenburg, Germany).
Indicated HASMCs were inoculated in 6-well plates (1 × 105 cells/well) until 80% confluence. Afterwards, a sterile 10 μl plastic pipette tip was utilized to scratch the plates and cells were further cultured for 24 h. Image-Pro Plus 6.0 software (Media Cybernetics, Shanghai, China) was used to record cell movement at 0 and 24 h. Cell migratory capability was measured as: (original scratch width-current scratch width) / original scratch width.
Cell migration was also examined using Transwell chambers (8 μm; Corning Inc., Corning, NY, USA). HASMCs (5 × 104 cells) suspended in 100 μl serum-free DMEM were added into the upper chambers and DMEM (500 μl) containing 10% FBS was placed into the lower chambers. After treatment for 24 h, cotton swabs were utilized to gently wiped off the nonmigratory cells. The migratory cells were fixed in 4% formaldehyde, stained with 0.1% crystal violet solution and counted under an Eclipse Ti-s microscope (Olympus, Tokyo, Japan).
ChIP assay was implemented using EpiQuik Chromatin immunoprecipitation Assay Kit (AmyJet, Wuhan, China) following the manufacturer’s protocols. Briefly, HASMCs were fixed with 1% formaldehyde and then treated with glycine for 5 mins. Afterwards, the chromatin was sonicated into DNA fragments (200–400 bp), and anti-ATF4 and control anti-IgG (Abcam) were used to precipitate the chromatin. Then quantification of the precipitated DNA was performed using RT-qPCR.
ATF4 binding site in FGF21 promoter sequence was predicted by JASPAR website (https://jaspar.genereg.net/). Wild type (Wt) FGF21 promoter sequence containing ATF4 binding site and the mutant (Mut) sequence were separately subcloned into pGL3 vector (Promega Corporation, Fitchburg, WI, USA) to establish Wt or Mut pGL3-FGF21 promoter. Then these vectors were co-transfected with si-ATF4 or si-NC into HASMCs using Lipofectamine 3000 (Invitrogen). The luciferase activity was assessed with Dual-Luciferase Reporter Assay System (Promega Corporation) 48 h post-transfection.
Data are presented as the mean ± standard deviation. SPSS 21.0 software (IBM Co., Armonk, NY, USA) was used for statistical analysis. Differences between two groups were analyzed with Student’s t-test, while those among more groups were evaluated using analysis of variance (ANOVA) followed by Turkey’s
HASMCs were treated with different concentrations of Ang-II to mimic the
To probe the potential role of FGF21 in the
Subsequently, we explored the potential mechanism responsible for FGF21 upregulation in Ang-II-stimulated HASMCs. It was reported that FGF21 expression could be regulated by the transcription factor ATF4 [10]. Here, we tested whether ATF4 was involved in regulating FGF21 expression in HASMCs. As displayed in Fig. 3A–C, Ang-II dose-dependently upregulated AFT4 in HASMCs. Moreover, we searched JASPAR database using FGF21 promoter sequence and a ATF4-binding site in FGF21 promoter sequence was predicted (Fig. 3D, E). ChIP assay elucidated the binding relation between ATF4 and FGF21 promoter (Fig. 3F). Then, we knocked down ATF4 in HASMCs with si-ATF4. As shown by western blotting, knocking down ATF4 not only decreased ATF4 protein expression, but also caused the downregulation of FGF21 protein expression in HASMCs (Fig. 3G, H). Additionally, ATF4 silencing decreased the luciferase activity of Wt FGF21 promoter but had no significant impact on the luciferase activity after mutation (Fig. 3I), further confirming the binding relation between AFT4 and FGF21 promoter. The above results indicate that ATF4 activates FGF21 transcription in HASMCs.
To further elucidate the role of ATF4/FGF21 axis in AAA
AAA is a vascular degenerative disorder defined as irreversible dilation of abdominal aorta that occurs mostly in elderly men [16]. Patients with AAA are usually asymptomatic, but once a rupture occurs, the patient may suffer from severe abdominal pain, low blood pressure and hemorrhage and have a high risk of death [17]. It is estimated that the mortality rate is up to 90% upon AAA rupture [18]. Open and endovascular aneurysm repair surgery are the main therapeutic strategies for AAA; however, they are not applicable for small AAA (
VSMCs are the principal component of the tunica media of the aortic wall and exert their function in the maintenance of vascular tone [21]. Emerging evidence has demonstrated that dysfunction of VSMCs, including excessive proliferation and migration and phenotype switch, contributes to the progression of vascular diseases, including AAA [22]. The fully differentiated VSMCs show a contractile phenotype and in response to vascular injury, VSMCs switch from a contractile state to a synthetic phenotype, characterized by elevated proliferative and migrative capabilities and decreased levels of contractile markers [23]. Here we established an AAA model in HASMCs induced by Ang-II and probed the potential role of FGF21 in Ang-II-stimulated HASMCs.
FGF21, a key regulator of metabolism, has been indicated to exert significant effects on the development of multiple vascular disorders. For example, in pulmonary arterial hypertension, FGF21 alleviates endothelial dysfunction and inflammation induced by hypoxia by regulating miR-27b mediated PPARγ pathway [24]. FGF21 protects against atherosclerosis by inhibiting vascular endothelial cell pyroptosis mediated by NLRP3 inflammasome [25]. Importantly, a high level of FGF21 in the plasma of patients with AAA was observed and FGF21 expression was positively correlated with AAA diameters and hypertension rate [7]. This indicated a close correlation between FGF21 the disease progression. Consistent with the previous study mentioned above, we found in this study that Ang-II dose-dependently induced FGF21 expression in HASMCs. Then, loss-of-function assays were implemented to examine the role of FGF21 in regulating HASCM proliferation, migration and phenotype switch. The results displayed that FGF21 silencing significantly inhibited the proliferative and migratory capabilities as well as phenotype switch of HASMCs, indicating that FGF21 might exert a promoting effect on the progression of AAA.
To explore the upregulation mechanism of FGF21 in Ang-II-treated HASMCs, bioinformatics analysis and a series of assays were performed. It was found that ATF4 was upregulated as the concentration of Ang-II increased in HASMCs and ATF4 activated FGF21 transcription by binding to its promoter. These results were in accord with previous studies which showed that FGF21 promoter has three response elements for ATF4 and ATF4 can induce FGF21 upregulation [9,10]. ATF4 is a widely expressed mammalian DNA binding protein that is implicated in a variety of pathological and physiological processes, such as autophagy, drug resistance and apoptosis [26,27]. It has been shown that ATF4 upregulation can induce VSMC to proliferate [28]. ATF4 is involved in vascular injury through the activation of a signaling pathway involving PERK, eIF2α and CHOP, key molecules in endoplasmic reticulum stress [29]. Additionally, it was demonstrated that ATF4 displayed an increased level in Ang-II-treated murine aortas [11]. To further verify the role of ATF4/FGF21 axis in regulating the behaviors of Ang-II-induced HASMCs, rescue experiments were conducted. The results revealed that knocking down ATF4 markedly restrained the proliferation and migration and decreased expression of markers for the contractile phenotype of HASMCs. However, these effects were abated by FGF21 overexpression, indicating that ATF4/FGF21 axis contributed to the pathogenesis of AAA.
In conclusion, we probed the role of FGF21 in the Ang-II-induced AAA model in HASMCs. The results reveal that ATF4 transcriptionally upregulates FGF21 to promote the proliferation, migration and phenotype switch of Ang-II-treated HASMCs. Our findings might provide a novel therapeutic strategy for AAA.
None.
This work was supported by Suzhou “Ke Jiao Xing Wei” Youth Science and Technology Development Program (No. KJXW2020064) and Changshu City Pharmaceutical Science and Technology Project (No. cswsq202001).
The authors declare no conflicts of interest.
View Full Text | Article as PDF |
Abstract | Figure & Table |
Pubmed | PMC |
Print this Page | Export to Citation |
ⓒ 2019. The Korean Journal of Physiology & Pharmacology. Powered by INFOrang Co., Ltd